drugset / Trial / NCT03896230

Ketamine for Pain in the Emergency Department

NCT03896230 ↗

Phase 4 Terminated 11 enrolled Hackensack Meridian Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will prospectively compare the mean Numerical Rating Scale (NRS) pain score reduction amongst three recommended dosing strategies of intravenous ketamine (0.1 mg/kg, 0.2 mg/kg, and 0.3mg/kg) for acute pain in the emergency department (ED).This study will also examine the frequency of adverse events secondary to ketamine including fatigue, dizziness, nausea, headache, feeling of unreality, changes in hearing or vision, mood changes, generalized discomfort, and hallucinations, changes in vital signs. Subgroups for exploratory analysis based on the need for rescue analgesia within two hours of ketamine administration, adequate pain relief, previous opioid tolerance, and age (adults \< 65 years old and \> 65 years old).

Timeline

Start
2019-05-03
Primary completion
2019-12-20
Completion
2019-12-20

Outcome

Outcome not reported

Stopped: “Due to resource limitations the study was on hold and was then terminated.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 0.1 mg/kg Intravenous
Comparator Ketamine Small molecule 0.2 mg/kg Intravenous
Comparator Ketamine Small molecule 0.3 mg/kg Intravenous

Indications

No indication recorded.